Market Research Reports, Inc.

Global Cervical Cancer Diagnostic Testing Market to Grow at a CAGR of 6.90% During the Period 2016 - 2020; Finds New Report

Market Research Reports, Inc. has announced the addition of “Global Cervical Cancer Diagnostic Testing Market 2016 - 2020” research report to their website


Lewes, DE -- (SBWIRE) -- 01/24/2017 -- Report forecast the global cervical cancer diagnostic testing market to grow at a CAGR of 6.90% during the period 2016-2020.

The global cervical cancer diagnostic testing market is growing steadily, primarily due to the availability and awareness of the programs in the developed countries. This test enables women aged 21 years and above to get screened, making most of the pre-cancerous lesions identifiable at stages when they can be treated easily. In the US, National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides low-cost even free cervical cancer screening for uninsured and low-income women.

As per the Affordable Care Act, all health insurance plans initiated after September 23, 2010, should provide recommended cervical cancer screening tests to end-users. In developing countries, with the widespread awareness programs by public organizations like the WHO along with government initiatives, visual inspection with acetic acid (VIA) and Lugol's iodine (VILI) are being performed to screen women. This initiative is expected to raise the market demand for cervical cancer screening and diagnostic tests.

The report covers the present scenario and the growth prospects of the global cervical cancer diagnostic testing market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of cervical cancer testing products used to perform cervical cancer screening.

The market is divided into the following segments based on geography:
- Americas

According to the report, one driver in the market is reimbursement policies. Most of the developed countries have specific agencies that have reimbursement policies to motivate and support women to undergo diagnostic tests. Agencies such as Wittenberg Weiner Consulting (WWC) and Wisconsin Well Women Program (WWWP) in the US reimburse an office visit for a pelvic exam, Pap smear test, HPV test, colposcopy, or other invasive diagnostic procedures, case management, and administrative fees. Similarly, diagnostic clinics have also started including cervical cancer diagnostics tests in their reimbursement policies. For Instance, Roche's cobas HPV Test is covered by Selah Genomics in its own certified laboratory. These favorable reimbursements coupled with the government initiatives will drive the cervical cancer diagnostic testing market during the forecast period.

Further, the report states that one challenge in the market is rising awareness toward cervical cancer over-screening. The medical authorities worldwide suggest that HPV test should replace current Pap smear test as the primary cervical cancer screening. Till now, most of the governments in the developed countries recommended women, to undergo Pap smear test once in every two years. With the adoption of the HPV testing, which suggests women undergo the test once in every five years, not only the over-screening will be reduced, but also the governments can save on overall healthcare budgets. Based on Roche's Athena clinical trial, the FDA acknowledged their cobas HPV test and recommended HPV testing as a replacement to Pap smear test.

Global Cervical Cancer Diagnostic Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

key players in the global cervical cancer diagnostic testing market: Abbott Molecular, Becton, Dickinson & Company, Hologic, Qiagen, Quest Diagnostics, and Roche Molecular Diagnostics.

Other Prominent Vendors in the market are: Arbor Vita, Autogenomics, bioMérieux, BioVantra, Cancer Genetics, Cepheid, Cervia Diagnostics, Cytoimmun, DAAN Gene, Delphi Bioscience, DiaCarta, Fujirebio, Genera Biosystems, Greiner Bio-One, Guided Therapeutics, GynaeHealth, IncellDx, Micromedic Technologies, Norchip, OncoHealth, OralDNA Labs, Seegene, Solopap International, and Trovagene.

Market driver
- Increasing global activities by public organizations.
- For a full, detailed list, view our report

Market challenge
- Rising awareness toward cervical cancer over-screening.
- For a full, detailed list, view our report

Market trend
- Development of new diagnostic platforms.
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Spanning over 111 pages and 84 Exhibits "Global Cervical Cancer Diagnostic Testing Market 2016 - 2020" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Market segmentation by test type, Market segmentation by technology, Market segmentation by method, Market segmentation by end-user, Geographical segmentation, Buying criteria, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.

For more information Visit at:

Related Reports;

Global Electrophysiology Devices Market 2016-2020 - Visit at -

Global Peritoneal Dialysis Market 2016-2020 - Visit at -

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: